Sugi Predict

Sugi Predict / Compounds / SCHEMBL2983115

SCHEMBL2983115

SCHEMBL2983115

Nc1nc([C@@H]2OC[C@@H](O)[C@@H](O)[C@H]2O)nc2nc[nH]c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.45
▸ GDA Q9Y2T3 1/20 0.45
▸ PI4KA P42356 2/20 0.36
▸ PI4K2B Q8TCG2 2/20 0.36
▸ PI4K2A Q9BTU6 2/20 0.36
▸ PI4KB Q9UBF8 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ XDH P47989 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ AURKB Q96GD4 1/20 0.36
▸ CDK2 P24941 3/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ POLA1 P09884 1/20 0.33
▸ PNP P00491 1/20 0.33
▸ ADK P55263 1/20 0.32
▸ CDK1 P06493 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27761338 0.99 PDPK1 (0.44) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL2117131 0.97 PDPK1 (0.45) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL7638547 0.85 PDPK1 (0.41) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL2983106 0.79 ADORA2A (0.34) ADORA2AADORA1PNPADK
SCHEMBL1994118 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB
SCHEMBL4436406 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB
SCHEMBL5182602 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB
SCHEMBL2636634 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB
SCHEMBL2010793 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB
SCHEMBL8509311 0.77 PDPK1 (0.43) PDPK1GDALMNAKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017703-B1 PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME NANOGEN RECOGNOMICS GMBH (DE) 2004-04-28 — — EP claimed
EP-1017704-B1 USE OF A PENTOPYRANOSYL NUCLEOSIDE CONTAINING CONJUGATE FOR PRODUCING AN ARRAY NANOGEN RECOGNOMICS GMBH (DE) 2004-02-25 — — EP claimed
EP-1019423-B1 METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE NANOGEN RECOGNOMICS GMBH (DE) 2003-02-26 — — EP claimed
US-7777024-B2 Process for preparing a pentopyranosyl nucleic acid conjugate AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) 2010-08-17 — — US disclosed
US-20090221793-A1 PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE SANOFI-AVENTIS S.A. (FR) 2009-09-03 — — US disclosed
US-7501506-B2 Pentopyranosyl nucleic acid conjugates NANOGEN RECOGNOMICS GMBH (DE) 2009-03-10 — — US disclosed
US-7153955-B2 Pentopyranosyl nucleic acid arrays, and uses thereof NANOGEN RECOGNOMICS GMBH (DE) 2006-12-26 — — US disclosed
US-20060270840-A1 Pentopyranosyl nucleic acid conjugates SANOFI-AVENTIS S.A. (FR) 2006-11-30 — — US disclosed
US-20050053945-A1 Process for the preparation of a pentopyranosyl conjugate NANOGEN RECOGNOMICS GMBH 2005-03-10 — — US disclosed
US-20040198966-A1 Pentopyranosylnucleoside, its preparation and use NANOGEN RECOGNOMICS GMBH 2004-10-07 — — US disclosed
EP-1017703-B1 PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME NANOGEN RECOGNOMICS GMBH (DE) 2004-04-28 — — EP disclosed
EP-1017704-B1 USE OF A PENTOPYRANOSYL NUCLEOSIDE CONTAINING CONJUGATE FOR PRODUCING AN ARRAY NANOGEN RECOGNOMICS GMBH (DE) 2004-02-25 — — EP disclosed
US-6613894-B1 Bonding the nucleoside to a solid support, deprotecting using an acid, reacting with a nucleoside phosphoramidite; oxidizing and coupling a biomolecule to the product NANOGEN RECOGNOMICS GMBH (DE) 2003-09-02 — — US disclosed
US-6608186-B1 Of given formula; use for the production of a therapeutic, diagnostic and/or electronic component; use in the construction of supramolecular units NANOGEN RECOGNOMICS GMBH (DE) 2003-08-19 — — US disclosed
US-20030039997-A1 Pentopyranosyl nucleic acid arrays, and uses thereof AVENTIS RESEARCH AND TECHNOLOGIES GMBH & CO. KG (DE) 2003-02-27 — — US disclosed
EP-1019423-B1 METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE NANOGEN RECOGNOMICS GMBH (DE) 2003-02-26 — — EP disclosed
US-6506896-B1 Conjugated to peptides, proteins, nucleic acids, antibodies, RNA, or DNA; medical diagnosis, electronics NANOGEN RECOGNOMICS GMBH (DE) 2003-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221793-A1 PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE RNGTT, NT5C3B, FUT6 PDPK1 3948/4885GDA 125/4885PI4KA 2291/4885
US-20040198966-A1 Pentopyranosylnucleoside, its preparation and use FUT6, ST3GAL3, FUT5 PDPK1 3547/4885GDA 302/4885PI4KA 3726/4885
US-20050053945-A1 Process for the preparation of a pentopyranosyl conjugate FUT6, FUT5, FUCA2 PDPK1 4222/4885GDA 447/4885PI4KA 3956/4885
US-20060270840-A1 Pentopyranosyl nucleic acid conjugates FUT6, RNGTT, B3GAT3 PDPK1 4331/4885GDA 254/4885PI4KA 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.